Exponent, Inc.
NASDAQ:EXPOConsulting Services
-$0.25 today
- Market cap
- $4.17B
- Beta
- 0.73
- P/E (TTM)
- 25.9
- EPS (TTM)
- $2.19
- Dividend yield
- 2.15%
Volume 0.40M
Average 0.60M
EXPO Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Exponent, Inc.NASDAQ: EXPO
Research & Development · Q3 FY2026 · quarter ended Oct 2026
Research & development remains negative
Q3 FY2026 research & development was $0, compared with $0 a year earlier. Trailing-twelve-month research & development was $0.
Context
- Research & development amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
- Research & development increased in 0 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly research & development holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2026-01-02 | 0 | — |
| FY2024 | 2025-01-03 | 0 | — |
| FY2023 | 2023-12-29 | 0 | — |
| FY2022 | 2022-12-30 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Research & Development vs competitors
How EXPO compares with its peers on the latest reported figures
- EXPO's LTM Oct 2026 research & development of $0 is the highest of the 11 companies compared; the peer median is $0.
- Research & development amounts to 0.0% of revenue for EXPO, versus a peer median of 0.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Oct 2026 | $0 | — | — | 0.0% | |
| LTM Sep 2026 | $0 | — | — | 0.0% | |
| LTM Sep 2026 | $0 | — | — | 0.0% | |
| LTM Jun 2026 | $0 | — | — | 0.0% | |
| LTM Oct 2026 | $0 | — | — | 0.0% | |
| LTM Jun 2026 | $0 | — | — | 0.0% | |
LGNLegence Corp. Class A Common stock | LTM Sep 2026 | $0 | — | — | 0.0% |
| LTM Sep 2026 | $0 | -100.0% | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| LTM Apr 2026 | $0 | — | — | 0.0% | |
| LTM Apr 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding EXPO) | $0 | -100.0% | — | 0.0% | |
Competitors are the stored peer set for EXPO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Jan 2025 | FY2025 Jan 2026 |
|---|---|---|---|---|---|
| Revenue | 466.27M | 513.29M | 536.77M | 558.51M | 582.01M |
| Cost of Revenue | 342.06M | 348.79M | 401M | 416.23M | 436.71M |
| Gross Profit | 124.21M | 164.5M | 135.76M | 142.28M | 145.31M |
| Gross Margin | 26.6% | 32.0% | 25.3% | 25.5% | 25.0% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 293.33M | 287.9M | 24.44M | 22.73M | 25.52M |
| Operating Expenses | 15.28M | 23.66M | 24.44M | 22.73M | 25.52M |
| Depreciation & Amortization | 6.49M | 7.08M | 8.92M | 9.69M | 10.08M |
| EBITDA | 132.32M | 139.31M | 144.81M | 157.06M | 157.38M |
| EBITDA Margin | 28.4% | 27.1% | 27.0% | 28.1% | 27.0% |
| Operating Income | 108.93M | 140.84M | 111.32M | 119.56M | 119.79M |
| Operating Margin | 23.4% | 27.4% | 20.7% | 21.4% | 20.6% |
| Interest Income | 66K | 2.1M | 7.15M | 10M | 9.31M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 16.91M | (8.61M) | 24.57M | 27.81M | 27.51M |
| Income Before Tax | 125.84M | 132.23M | 135.9M | 147.37M | 147.3M |
| Pre-Tax Margin | 27.0% | 25.8% | 25.3% | 26.4% | 25.3% |
| Income Tax Expense | 24.64M | 29.9M | 35.56M | 38.37M | 41.29M |
| Net Income | 101.2M | 102.33M | 100.34M | 109M | 106.01M |
| Net Margin | 21.7% | 19.9% | 18.7% | 19.5% | 18.2% |
| EPS (Basic) | 1.92 | 1.98 | 1.96 | 2.13 | 2.08 |
| EPS (Diluted) | 1.90 | 1.96 | 1.94 | 2.11 | 2.07 |
| Weighted Avg Shares | 52.61M | 51.73M | 51.15M | 51.13M | 50.9M |
| Weighted Avg Shares (Diluted) | 53.33M | 52.28M | 51.64M | 51.57M | 51.24M |
Exponent, Inc.
NASDAQ:EXPO
Intrinsic Alpha fair value
Locked
Current Price
$87.69
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.